Invasive Carcinoma — Trials

Invasive Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,812 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 603
Recruiting: 301
Ph III recruiting: 36
Growth YoY: +27.2%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (282)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06877676	Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use	approved for marketing	—	—	Janssen Research & Development, LLCINDUSTRY	0	Sep 25, 2026	clinicaltrials
NCT04377152	Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer	approved for marketing	—	—	University of California, San FranciscoOTHER	1	Mar 1, 2021	clinicaltrials